Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-B/Bcl-2 pathway

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1951-1955

  Qian, Chunfa ^a   Li, Ping ^b   Yan, Wei ^a   Shi, Lei ^c   Zhang, Junxia ^a   Wang, Yingyi ^a   Liu, Hongyi ^a   You, Yongping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c JIANGSU UNIVERSITY   (China)

Author keywords

Chemotherapy; Glioma; NF B Bcl 2; Osteopontin

Indexed keywords

CISPLATIN; OSTEOPONTIN; PROTEIN BCL 2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMALL INTERFERING RNA; TEMOZOLOMIDE; DACARBAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; ASTROCYTOMA CELL; B CELL LYMPHOMA; CHEMOTHERAPY; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; GLIOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; APOPTOSIS; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DACARBAZINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; NF-KAPPA B; OSTEOPONTIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84916631714     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2951     Document Type: Article

References (33)

1. Field KM, Drummond KJ, Yilmaz M, Tacey M, Compston D, Gibbs P and Rosenthal MA: Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive dataset. J Clin Neurosci 20: 783-789, 2013.
2. Koshkin PA, Chistiakov DA and Chekhonin VP: Role of microRNAs in mechanisms of glioblastoma resistance to radio? and chemotherapy. Biochemistry (Mosc) 78: 325-334, 2013.
3. Shevde LA, Das S, Clark DW and Samant RS: Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10: 71-81, 2010.
4. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K and Lucin K: Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res 14: 293-298, 2008.
5. Toy H, Yavas O, Eren O, Genc M and Yavas C: Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol Oncol Res 15: 203-207, 2009.
6. Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch CA, Everts V, Van Noorden CJ and Sodek J: Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 132: 39-48, 2011.
7. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P and You Y: Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 12: 765-775, 2010.
8. Rothwarf DM, Zandi E, Natoli G and Karin M: IKK-gamma is an essential regulatory subunit of IkappaB kinase complex. Nature 395: 297-300, 1998.
9. Liu R, Tan J, Lin Y, Jia R, Yang W, Liang C, Geng Y and Qiao W: HIV-1 Vpr activates both canonical and noncanonical NF-B pathway by enhancing the phosphorylation of IKKα/β. Virology 439: 47-56, 2013.
10. Li Z, Guo Y, Jiang H, Zhang T, Jin C, Young CY and Yuan H: Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer 14: 276, 2014.
11. Li F, Huang L, Su XL, Gu QH and Hu CP: Inhibition of nuclear factor-B activity enhanced chemosensitivity to cisplatin in human lung adeno-carcinoma A549 cells under chemical hypoxia conditions. Chin Med J (Engl) 126: 3276-3782, 2013.
12. Fuke Y, Hishinuma M, Namikawa M, Oishi Y and Matsuzaki T: Wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate induces apoptosis in human breast cancer by possible involvement of the NF-B pathways. Nutr Cancer 66: 879-887, 2014.
13. Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng Y, Lv J, Song Z, Li Y, Ji L, Pan S, Jiang H and Sun B: Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-B signaling pathway. Biochem Pharmacol 88: 322-333, 2014.
14. Du QH, Xu YB, Zhang MY, Yun P and He CY: Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-B activity. World J Gastroenterol 19: 5485-5492, 2013.
15. Wang H, Wang H, Zhang W, Huang HJ, Liao WS and Fuller GN. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951, 2004.
16. McFarland BC, Hong SW, Rajbhandari R, Twitty GB Jr, Gray GK, Yu H, Benveniste EN and Nozell SE. NF-B-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One 8: e78728, 2013.
17. Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK and Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-B, interleukin-8 pathway. Oncogene 31: 4054-4066, 2012.
18. Yin BL, Hao H, Wang YY, Jiang YJ and Xue S: Downregulating osteopontin reduces angiotensin II-induced inflammatory activation in vascular smooth muscle cells. Inflamm Res 58: 67-73, 2009.
19. Dumitru CA, Weller M and Gulbins E: Ceramide metabolism determines glioma cell resistance to chemotherapy. J Cell Physiol 221: 688-695, 2009.
20. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A and Le QT: The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 5: e9633, 2010.
21. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sørensen ES and Denhardt DT: Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728-736, 2002.
22. Song G, Ming Y, Mao Y, Bao S and Ouyang G: Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells. Exp Biol Med (Maywood) 233: 1537-1545, 2008.
23. Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 23: 367-387, 2004.
24. Arlt A and Schäfer H: NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40: 336-347, 2002.
25. Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR and Evers BM: Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 132: 127-134, 2002.
26. Dhandapani KM, Mahesh VB and Brann DW: Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102: 522-538, 2007.
27. Jani TS, DeVecchio J, Mazumdar T, Agyeman A and Houghton JA: Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285: 19162-19172, 2010.
28. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
29. Guensberg P, Wacheck V, Lucas T, Monia B, Pehamberger H, Eichler HG and Jansen B: Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 48: 189-195, 2002.
30. Gielen PR, Aftab Q, Ma N, Chen VC, Hong X, Lozinsky S, Naus CC and Sin WC: Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology 75: 539-548, 2013.
31. Fennell DA: Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer 4: 307-313, 2003.
32. Heckman CA, Mehew JW and Boxer LM: NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908, 2002.
33. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S and Bold RJ: Targeting Bcl-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56: 46-54, 2005.